At present, levodopa (L DOPA) is the standard of care for treating the motor symptoms, but it is not curative, and prolonged use can engender L-DOPA induced dyskinesia (LID). A hallmark of PD is the progressive degeneration and loss of dopaminergic neurons in the substantia nigra (SN) and basal ganglia (BG), leading to pronounced motor symptoms including bradykinesia, tremor, rigidity, gait dysfunction and postural instability. Moreover, early-onset PD is also increasing. Parkinson's disease (PD) is the second most common neurodegenerative disease with an increasing prevalence as a function of age. The present disclosure relates to compounds, compositions, and methods for treating disorders associated with muscarinic acetylcholine receptor dysfunction. 17, 2017, the entire contents of each of which are hereby incorporated by reference. 17, 2018, which claims the benefit of U.S. ยง 371, of International Application Number PCT/US2018/056233, filed Oct.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |